Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William P Tew

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology|July 27, 2021
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapyDerman Basaran, Thomas Boerner, Jessa Suhner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
The Oncologist|August 18, 2009
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancerDennis S Chi, Rebecca Phaëton, Thomas J Miner, et al.
Gynecologic Oncology|January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancerKaren A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2018
Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research GroupTanya M Wildes, Ronald J Maggiore, William P Tew, et al.
Gynecologic Oncology|February 22, 2023
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trialAaron M Praiss, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology|May 23, 2019
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation statusMarina Stasenko, Paulina Cybulska, Noah Feit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini, Govind Ragupathi, Chandra Hood, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A Matulonis, Julie Lee, Brian Lasonde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401Arti Hurria, Constance T Cirrincione, Hyman B Muss, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|July 27, 2021
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapyDerman Basaran, Thomas Boerner, Jessa Suhner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
The Oncologist|August 18, 2009
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancerDennis S Chi, Rebecca Phaëton, Thomas J Miner, et al.
Gynecologic Oncology|January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancerKaren A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2018
Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research GroupTanya M Wildes, Ronald J Maggiore, William P Tew, et al.
Gynecologic Oncology|February 22, 2023
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trialAaron M Praiss, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology|May 23, 2019
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation statusMarina Stasenko, Paulina Cybulska, Noah Feit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini, Govind Ragupathi, Chandra Hood, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A Matulonis, Julie Lee, Brian Lasonde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401Arti Hurria, Constance T Cirrincione, Hyman B Muss, et al.
Pageof 12